Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study.
Agalsidase beta
Anti-drug antibodies
Enzyme replacement therapy
Fabry disease
Infusion time
Infusion-associated reactions
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 Feb 2024
02 Feb 2024
Historique:
received:
15
09
2023
accepted:
19
01
2024
medline:
3
2
2024
pubmed:
3
2
2024
entrez:
2
2
2024
Statut:
epublish
Résumé
Fabry disease is a rare progressive X-linked lysosomal storage disease caused by mutations in the GLA gene that encodes α-galactosidase A. Agalsidase beta is a recombinant enzyme replacement therapy authorized in Europe at a standard dose of 1.0 mg/kg intravenously every other week at an initial infusion rate of ≤ 0.25 mg/min until patient tolerance is established, after which the infusion rate may be increased gradually. However, specific practical guidance regarding the progressive reduction in infusion time is lacking. This study investigated a new and specific protocol for reducing agalsidase beta infusion time in which a stable dosage of 15 mg/h is infused for the first four months, and the infusion rate is increased progressively from 15 to 35 mg/h for the subsequent four infusions. The shortest infusion time is reached after six months and maintained thereafter. The incidence of infusion-associated reactions (IARs) and the development of anti-drug antibodies were analyzed, and the disease burden and the clinical evolution of the disease at 12 months were evaluated. Twenty-five of the 31 patients were naïve to enzyme or chaperone treatment at baseline and six patients had been switched from agalsidase alfa. The reduced infusion time protocol was well tolerated. Only one patient exhibited an IAR, with mild symptoms that resolved with low-dose steroids. Six patients globally seroconverted during treatment (4 with a classic phenotype and 2 with late-onset disease). All but three patients were seronegative at month 12. All patients were stable at the study's end (FAbry STabilization indEX value < 20%); reducing infusion time did not negatively impact clinical outcomes in any patient. The perceived medical assessment showed that the quality of life of all patients improved. The study demonstrates that reducing agalsidase beta infusion time is possible and safe from both an immunogenic and clinical point of view. The use of a low infusion rate in the first months when the probability of onset of the development of antibodies is higher contributed to very limited seroconversion to antibody-positive status.
Sections du résumé
BACKGROUND
BACKGROUND
Fabry disease is a rare progressive X-linked lysosomal storage disease caused by mutations in the GLA gene that encodes α-galactosidase A. Agalsidase beta is a recombinant enzyme replacement therapy authorized in Europe at a standard dose of 1.0 mg/kg intravenously every other week at an initial infusion rate of ≤ 0.25 mg/min until patient tolerance is established, after which the infusion rate may be increased gradually. However, specific practical guidance regarding the progressive reduction in infusion time is lacking. This study investigated a new and specific protocol for reducing agalsidase beta infusion time in which a stable dosage of 15 mg/h is infused for the first four months, and the infusion rate is increased progressively from 15 to 35 mg/h for the subsequent four infusions. The shortest infusion time is reached after six months and maintained thereafter. The incidence of infusion-associated reactions (IARs) and the development of anti-drug antibodies were analyzed, and the disease burden and the clinical evolution of the disease at 12 months were evaluated.
RESULTS
RESULTS
Twenty-five of the 31 patients were naïve to enzyme or chaperone treatment at baseline and six patients had been switched from agalsidase alfa. The reduced infusion time protocol was well tolerated. Only one patient exhibited an IAR, with mild symptoms that resolved with low-dose steroids. Six patients globally seroconverted during treatment (4 with a classic phenotype and 2 with late-onset disease). All but three patients were seronegative at month 12. All patients were stable at the study's end (FAbry STabilization indEX value < 20%); reducing infusion time did not negatively impact clinical outcomes in any patient. The perceived medical assessment showed that the quality of life of all patients improved.
CONCLUSIONS
CONCLUSIONS
The study demonstrates that reducing agalsidase beta infusion time is possible and safe from both an immunogenic and clinical point of view. The use of a low infusion rate in the first months when the probability of onset of the development of antibodies is higher contributed to very limited seroconversion to antibody-positive status.
Identifiants
pubmed: 38308295
doi: 10.1186/s13023-024-03049-5
pii: 10.1186/s13023-024-03049-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Subventions
Organisme : Dialecticon srl, Italy
ID : not applicable
Informations de copyright
© 2024. The Author(s).
Références
Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;530.
Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 2001;345(1):9–16.
doi: 10.1056/NEJM200107053450102
pubmed: 11439963
Schiffmann R, Kopp JB, Austin HA 3, et al. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743–9.
doi: 10.1001/jama.285.21.2743
pubmed: 11386930
Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of fabry disease: an international cohort study. J Med Genet. 2018;55(5):351–8.
doi: 10.1136/jmedgenet-2017-104863
pubmed: 29437868
European Medicines Agency (EMA). 2022 Replagal (Agalsidase alfa): Summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/replagal Accessed July 2023.
Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288–96.
doi: 10.1136/jmedgenet-2016-104178
pubmed: 27834756
European Medicines Agency (EMA). 2023 Fabrazyme (Agalsidase Beta): Summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/fabrazyme Accessed July 2023.
Wilcox WR, Linthorst GE, Germain DP, et al. Anti-alpha-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105(3):443–9.
doi: 10.1016/j.ymgme.2011.12.006
pubmed: 22227322
Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with fabry disease. J Am Soc Nephrol. 2018;29(9):2265–78.
doi: 10.1681/ASN.2018030329
pubmed: 30093456
pmcid: 6115664
Stappers F, Scharnetzki D, Schmitz B, et al. Neutralising anti-drug antibodies in fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis. 2020;43(2):334–47.
doi: 10.1002/jimd.12176
pubmed: 31587315
Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in fabry disease. J Am Soc Nephrol. 2016;27(1):256–64.
doi: 10.1681/ASN.2014121226
pubmed: 25933799
Lenders M, Brand E. Assessment and impact of dose escalation on anti-drug antibodies in fabry disease. Front Immunol. 2022;131024963.
Rombach SM, Aerts JM, Poorthuis BJ, et al. Long-term effect of antibodies against infused alpha-galactosidase A in fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE. 2012;7(10):e47805.
doi: 10.1371/journal.pone.0047805
pubmed: 23094092
pmcid: 3477102
Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66(4):1589–95.
doi: 10.1111/j.1523-1755.2004.00924.x
pubmed: 15458455
Mignani R, Pieruzzi F. Safety of a protocol for reduction of agalsidase beta infusion time in fabry disease: an Italian multi-centre study. Mol Genet Metab Rep. 2022;30100838.
Mignani R, Pieruzzi F, Berri F, et al. FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in fabry disease. Clin Kidney J. 2016;9(5):739–47.
doi: 10.1093/ckj/sfw082
pubmed: 27679722
pmcid: 5036909
Duro G, Zizzo C, Cammarata G et al. Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci. 2018;19(12).
Lawshe C. A quantitative approach to content validity. Pers Psychol. 1975;28563–75.
Polit DF, Beck CT. The content validity index: are you sure you know what’s being reported? Critique and recommendations. Res Nurs Health. 2006;29(5):489–97.
doi: 10.1002/nur.20147
pubmed: 16977646
Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP. Successful reinstitution of agalsidase beta therapy in fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med. 2008;10(5):353–8.
doi: 10.1097/GIM.0b013e318170f868
pubmed: 18496035
Sanchez-Purificacion A, Castellano A, Gutierrez B et al. Reduction of agalsidase beta infusion time in patients with fabry disease: a case series report and suggested protocol. Mol Genet Metab Rep. 2021;27100755.
de Juan-Ribera J, Llopis FAG, Muñoz EB. Safety reduction of agalsidase beta infusion time in fabry disease patients. Abstract 63 Mol Genet Metab. 2022;135(2):35–S6.
doi: 10.1016/j.ymgme.2021.11.078
Riccio E, Zanfardino M, Franzese M, et al. Stepwise shortening of agalsidase beta infusion duration in fabry disease: clinical experience with infusion rate escalation protocol. Mol Genet Genomic Med. 2021;9(5):e1659.
doi: 10.1002/mgg3.1659
pubmed: 33755336
pmcid: 8172210
Lee CS, Tsurumi M, Eto Y. Safety and tolerability of agalsidase beta infusions shorter than 90 min in patients with fabry disease: post-hoc analysis of a Japanese post-marketing study. Orphanet J Rare Dis. 2023;18(1):209.
doi: 10.1186/s13023-023-02803-5
pubmed: 37488580
pmcid: 10367408
Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35(2):227–43.
doi: 10.1007/s10545-011-9400-y
pubmed: 22037707
Tsukimura T, Tayama Y, Shiga T, Hirai K, Togawa T, Sakuraba H. Anti-drug antibody formation in Japanese fabry patients following enzyme replacement therapy. Mol Genet Metab Rep. 2020;25100650.
van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M. Antibodies against recombinant alpha-galactosidase A in fabry disease: subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126(2):162–8.
doi: 10.1016/j.ymgme.2018.11.008
pubmed: 30473480
Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94(3):319–25.
doi: 10.1016/j.ymgme.2008.03.003
pubmed: 18424138